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Background. Rotavirus (RV) infection is the first cause of acute 
viral gastroenteritis in children under five years of age all over 
the world; it mainly affects children between six and 24 months 
of age and can cause serious acute diarrhoea and dehydration. 
The aim of this study is to perform the budget impact analysis of 
universal rotavirus vaccination in the Local Health Unit (LHU) 
11 Empoli, Tuscany, Italy. 
Methods. An ad hoc mathematical simulation model was devel-
oped to evaluate the budget impact analysis of 5-years universal 
rotavirus vaccination. Particularly, incidence of rotavirus gastro-
enteritis (RVGE), hospitalizations, nosocomial diarrhoea, medical 
consultations, prescriptions and accesses to emergency department 
were taken into account in the analysis. The direct medical costs 
due to RV diarrhoea and the costs of vaccination campaign were 
considered as the main outcome measures in the study.
Results. The adoption of universal rotavirus vaccination cam-
paign for five years in the LHU 11 Empoli would result in rele-
vant savings due to the health cares avoided. These savings would 
overlapped the costs of vaccination yet from the second year after 
the introduction of vaccination. The saving for the Health Service 
would be 1.5 million Euro after five years of campaign.
Conclusions. Universal vaccination against rotavirus results 
clinically and economically favourable for both the Health Ser-
vice and the Society perspectives.  
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Summary
Introduction
Rotavirus (RV) infection is the first cause of acute viral 
gastroenteritis in children under five years of age all over 
the world; it mainly affects children between six and 24 
months of age and can cause serious acute diarrhoea, re-
sulting in dehydration (which can lead to death if rehydra-
tion therapy is not adequately administered) [1-9]. Most 
of the children infected by RV are under three years of 
age and many children get sick more than once.
Every year, in the developing countries, rotavirus acute 
viral gastroenteritis (RVGE) causes the death of about 
444,000 children; while in USA these diseases are re-
sponsible for a number of hospitalization between 
58,000 and 70,000 [10]. In Europe, each year, among the 
population under five years of age (about 23.6 millions) 
there are approximately 3.6 millions cases of RVGE, 
231 deaths, at least 87,000 hospitalizations and 700,000 
medical examinations related to this disease [2].
In industrialized countries, deaths caused by RV are rare 
because of easy and rapid access to primary cares, but 
the burden of this disease is very relevant, due to the 
high frequency of the infection [2].
Several studies, performed in different countries, show 
the impact of RVGE on primary cares and on hospitali-
zations, also in the economic perspective; these studies 
often demonstrate discordant results, probably due to the 
different study designs applied (methods, populations 
and aim) [11-21].
In Italy, RV disease has a remarkable clinical impact 
with repercussions on National Health System (medical 
examinations, accesses to emergency department, hospi-
talizations) and on families (absences from work, costs 
of drugs, dietetic products, diapers, etc.) [22].
As a matter of fact, RV is the main responsible for the 
hospitalizations due to diarrhoea (about 10,000 hospi-
talizations per year) in children under five years of age 
(about 1% in a birth cohort), with an average duration of 
hospitalization amounting to five days during the last ten 
years [23-25]. Infection can also be contracted in hospi-
tal, causing an increase of the average duration of hospi-
talization of five days [23, 24].
In Italy, RVGE must be notified in the Second Group 
of infection diseases (according to Ministerial Decree 
15/12/1990) as “infectious diarrhoea, not caused by 
Salmonella spp.”, but official surveillance data on inci-
dence of this disease are not available. However, there is 
a national surveillance system addressed to the charac-
terization of circulating RV strains; this system is part of 
the European surveillance system [26].
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RVGE is an infection preventable by vaccination. Now-
adays, two different vaccines against RV are available 
in Europe: Rotarix (GSK) and Rotateq (Sanofi Pasteur); 
they must be orally administered, respectively in two 
and three doses, in children sixth weeks old.
To evaluate the allocative efficiency of this vaccination, 
considering the limited resources of Health System, and 
to support the decision makers in management decisions, 
an economic evaluation on the introduction of universal 
vaccination against RV for all the newborns in the LHU 
11 Empoli, in Tuscany (Italy), for a period of five years, 
was carried out through a budget impact analysis.
Materials and methods
An had hoc mathematical simulation model, in Excel 
(Microsoft, Redmont, USA), was developed in order to 
perform the budget impact analysis of the introduction 
of RV vaccination in the LHU 11 Empoli. 
The clinical and economic impact related to the imple-
mentation of universal RV vaccination in a five-years 
period was compared with a no-vaccination scenario.
In the mathematical simulation, a vaccine coverage of 
90%, constant for five years, was supposed.
Considering the short horizon time of analysis, no dis-
count rates were applied to costs and benefits. The eco-
nomic evaluation considered the birth cohorts of the 
LHU 11 Empoli, that includes about 2,300 newborns 
per year.
After the literature review, the following parameters 
were included in the study: incidence of RVGE, hos-
pitalizations, accesses to emergency department, and 
medical consultations. Particularly, an analysis of the 
National Health System’s direct medical costs associ-
ated to the burden of RV disease was carried out. To 
achieve the budget analysis, not-medical direct costs 
(transport to the hospital, diapers consumptions, rehy-
dration solutions, drugs, special foods, etc.), and indirect 
ones (working days lost by the parents due to their sick 
children) were not considered, because they were both 
Societal expenses.
The parameters used in the mathematical simulation 
model are shown in Table I. Particularly, percentages 
and costs related to RVGE cases, hospitalizations, no-
socomial diarrhoea cases, medical consultations, pre-
scriptions and accesses to emergency department, were 
obtained from two Italian studies concerning economic 
evaluations [23, 27].
Vaccine data
Data on the efficacy of the RV vaccine used in the math-
ematical simulation model were obtained from a clinical 
study performed in several European countries, includ-
ing Italy [28].
The cost of the RV vaccine in the LHU 11 Empoli, cur-
rently of 36.50 Euro for each dose, plus 10% for taxes 
(price in 2013), was used to develop the economic anal-
ysis. No other costs (for example the cost for the further 
organization of the vaccine centre) was added because 
the vaccine, already available in co-payment, would 
have been administered at the same time of the first two 
vaccination sessions, according to the Tuscan vaccina-
tion schedule [29].
Sensitivity analysis
To evaluate the impact of the uncertainty related to the 
input data on the results, a sensitivity analysis was car-
ried out, applying a variation of ± 20% on the cost of the 
RV vaccine and on the percentages of hospitalizations, 
nosocomial diarrhoea cases, medical consultations, and 
accesses to emergency department. In addition, a vari-
ation on the vaccine coverage (from 90% to 80% and 
70%) was also applied [23].
Results
Data obtained from the simulation carried out using the 
mathematical model show that the universal vaccina-
tion against RV, in five years in the LHU11 Empoli, 
would cause a relevant reduction (47%) of the RVGE 
cases: 26,134 cases of RVGE in no-vaccine scenario and 
13,762 cases in vaccine scenario. In Table II, the cases 
of RV diarrhoea prevented with the introduction of the 
RV vaccination are shown.
Tab. I. parameters used in the mathematical simulation model to 
perform the budget impact analysis.
Incidence
%
Average costs 
per case (Euro)
rvge cases 45.45% -
hospitalizations due to rv 
diarrhoea 
1.82 % 1,463
Nosocomial diarrhoea cases 0.91% 2,000
medical consultations 22.73% 23.80
Accesses to emergency 
department 
7.70% 352.72
prescriptions 9.98
Tab. II. Clinical impact of rv vaccination in LhU 11 empoli: rvge cases 
prevented with the introduction of vaccination, divided by age.
RVGE cases 
prevented 
with the 
vaccination
 
Children age
0 years
1 
year
2 
years
3 
years
4 
years
Total
1st year of 
vaccination 825 0 0 0 0 825
2nd year of 
vaccination 825 825 0 0 0 1,650
3rd year of 
vaccination 825 825 825 0 0 2,474
4th year of 
vaccination 825 825 825 825 0 3,299
5th year of 
vaccination 825 825 825 825 825 4,124
Total 4,124 3,299 2,474 1,650 825 12,372
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Costs for hospitalizations, nosocomial diarrhoea cases, 
medical consultations, prescriptions and accesses to 
emergency department prevented with the RV vaccina-
tion are shown in Table III. The LHU 11 Empoli could 
save about 882,000 Euro for hospitalizations, 495,000 
Euro for nosocomial diarrhoea cases, 156,000 Euro for 
medical consultations, 66,000 Euro for prescriptions and 
785,000 Euro for the accesses to emergency department 
in five-years vaccination period.
Vaccination costs
Vaccination against RV for a birth cohort (2,300 new-
borns per year) in the LHU 11 Empoli would amount 
166,000 Euro per year, with a total cost of 831,000 Euro 
after five years from the introduction of the vaccine in 
the schedule.
Budget impact analysis
According to the mathematical method, the annual cost 
related to the RV disease for the LHU 11 Empoli with-
out the adoption of an immunization program would be 
about 916,000 Euro (Tab. IV). 
During the first year of RV vaccination, the costs for the 
Health Unit to take care of the remaining cases of RV 
disease, added to the costs related to vaccination, would 
exceed the costs related to the disease burden; from the 
second year, savings are registered and increase in the 
following years as shown in Figure 1. The total savings 
Tab. III. Costs for hospitalizations, nosocomial diarrhea cases, medical consultations, prescriptions, accesses to emergency department caused 
by rvge and prevented with the vaccination (euro). 
Hospitalizations 
for RV diarrhoea
Nosocomial 
diarrhoea 
cases
Medical 
consultations
Prescriptions
Accesses to 
emergency 
department
Total
1st year of vaccination 58,791.53 33,027.54 10,426.73 4,372.22 52,347.10 158,965.13
2nd year of vaccination 117,583.07 66,055.08 20,853.47 8,744.44 104,694.21 317,930.26
3rd year of vaccination 176,374.60 99,082.62 31,280.20 13,116.65 157,041.31 476,895.39
4th year of vaccination 235,166.13 132,110.16 41,706.93 17,488.87 209,388.42 635,860.51
5th year of vaccination 293,957.66 165,137.70 52,133.66 21,861.09 261,735.52 794,825.64
Totale 881,872.99 495,413.10 156,400.99 65,583.27 785,206.57 2,384,476.93
Tab. IV. rv disease costs with and without rv vaccination and budget difference (euro).
Budget difference (Euro) Year 1 Year 2 Year 3 Year 4 Year 5
rv disease costs without vaccination 916,139 916,139 916,139 916,139 916,139 
Costs for remaining cases of rv disease with vaccination 757,174 598,208 439,243 280,278 121,313 
vaccination cost 166,221 166,221 166,221 166,221 166,221 
Budget difference -7,256 151,709 310,674 469,640 628,605 
Total budget difference in 5 years-period  1,553,372 
Fig. 1. Costs of rv disease without rv vaccination compared with disease costs after the introduction of rv vaccination (as sum of rv 
disease costs and vaccination campaign costs).
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for the LHU 11 Empoli would be of 1,553,372 Euro at 
the end of the five years.
As shown in Figure 1, the savings due to the adoption of 
the RV vaccination would be registered after the second 
year of immunization program.
Also changing the input data in the mathematical meth-
od, the adoption of the universal RV vaccination pro-
gram for the newborns in the LHU 11 Empoli is still 
economically favourable for the payer (LHU) (Tab. V). 
Discussion and conclusions
Nowadays, also in Italy, infections caused by Rotavirus 
in children from zero to five years of age results in an 
high clinical and economic impact, in spite of the avail-
ability of effective vaccines.
The results of the analysis carried out show that the 
adoption of an universal vaccination programme against 
RV, in five years in the LHU 11 Empoli, Tuscany (Ita-
ly), would determine considerable savings related to the 
treatments and therapies avoided with the implementa-
tion of immunization campaign. These savings would 
exceed costs for vaccination since the second year of 
the vaccine programme. Therefore, also in more limited 
time horizon of analysis, for example 3 years, typical of 
budget impact evaluations, our results continued to be 
favourable with saving amounting to 455,128 Euro.30 
As a matter of fact, the RV vaccination cost represents 
the 0.5% of the annul pharmaceutic budget in the LHU 
11 Empoli, without considering the obtained saving. 
The results of the study would be more favourable, from 
the point of view of the Society, considering also not-
medical direct costs and indirect costs avoided with the 
introduction of immunization.
Data obtained agree with other studies carried out in Eu-
ropean countries, for example in France, but disagree with 
analysis performed in England and in the Netherlands, 
where vaccination against RV is not cost-effective in the 
current situation, and with the studies concerning United 
States, where RV vaccination would be cost-effective but it 
would not determine savings for the payer [10, 21, 30-32]. 
In spite of this, the RV universal vaccination for new-
borns was recently implemented in England.
In Italy, two studies demonstrated that the introduction of 
RV vaccination was favourable, particularly in terms of 
cost-effectiveness, at national and regional level [23, 27]. 
In addition, our results are consistent with data obtained 
in two other studies on RV vaccination conducted in the 
Province of Genoa (Northern Italy), and should be con-
sidered conservative if the RV hospitalisation code is 
attributed only to 65% of RV-positive cases and, conse-
quently, hospitalisation related to RV is underestimated, 
as showed in that analyses [33, 34].
In this study, a vaccination coverage of 90% was sup-
posed in order to evaluate the greatest impact of the RV 
vaccination. This assumption implies the underlying 
rationale that the co-administration of RV vaccine with 
hexavalent vaccine would determine the rapid achieve-
ment of high level of vaccination coverage. 
However, the sensitivity analysis demonstrates that, also 
reducing the vaccination coverage to 70%, as in other 
studies reported in literature, the favourable economic 
issue of rotavirus vaccination still stand [31, 32].
In this study, the effect of herd immunity was not taken 
into account: according to some authors, it would increase 
the overall effectiveness of RV vaccination  [32, 34, 37].
The study has some limitations: epidemiological data 
and costs were collected from a recent study and they 
were not directly calculated in our area, due to a gap of 
specific data [27].
However, data used in the mathematical simulation were 
consistent with local data obtained from health archives, 
considering that the underestimation about RV diarrhoea 
cases and hospitalizations is about 40% [24], due to the 
high number of cases of gastroenteritis with not-defined 
aetiology, related to the lack of sensitivity of the hospital 
discharge data system[20, 31, 32, 35, 38]. 
Indeed, the examination of the hospital discharge data of 
the period between 2004 and 2013 [36] 2013 [39] in the 
LHU 11 Empoli, shows that 337 children between zero 
and five years of age were hospitalized because of RV 
Tab. V. Total costs and saving in the five-years period: sensitivity analysis.
RV disease 
costs without 
vaccination (Euro)
Costs due to remaining 
cases of RV disease with 
vaccination (Euro)
Budget difference
(Euro)
model 4,580,693 3,027,322 1,553,372
vaccination coverage 80% 4,580,693 2,934,977 1,645,717
vaccination coverage 70% 4,580,693 2,842,632 1,738,062
% hospitalizations: -20% 4,311,501 2,913,184 1,398,317
% hospitalizations: +20% 4,816,236 3,127,192 1,689,045
% Nosocomial diarrhoea: -20% 4,339,193 2,900,148 1,439,046
% Nosocomial diarrhoea: +20% 4,799,193 3,142,384 1,656,810
% medical consultations: -20% 4,492,705 2,983,574 1,509,131
% medical consultations: +20% 4,651,978 3,062,764 1,589,214
% Accesses to emergency department: -20% 4,276,472 2,876,063 1,400,410
% Accesses to emergency department: +20% 4,824,070 3,148,328 1,675,742
vaccine cost: -20% 4,580,693 2,860,687 1,720,007
vaccine cost: +20% 4,580,693 3,159,802 1,420,892
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disease or they extended the period of hospitalization due 
to RV. They determine a total cost exceeding 500,000 
Euro, assuming real costs of hospitalization equal to Di-
agnosis-Related Groups (DRG) [37, 40] charges (even if 
it was demonstrated that these costs often exceeded the 
applied charges, especially in paediatric wards) [35, 38].
These hospitalizations concerned only diarrhoea cases 
in which a clear RV aetiology could be proved and these 
data are consistent with those reported in the study [1-3]. 
In this analysis, the costs for National Health System and 
costs for the families, that might result from possible ad-
verse drug reactions to vaccination, were not taken into 
account, because of the rarity of these events. In addi-
tion, costs for possible paediatric consultations at home 
were not considered in the mathematical simulation.
The budget impact analysis carried out demonstrates 
that the adoption of RV universal vaccination for the 
newborns cohorts in 5 years would be clinically and eco-
nomically favourable for both the Health Service and, 
consequently, the Society.
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